Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye disease

Journal of Ocular Pharmacology and Therapeutics

Volumn 27, Issue 1, 2011, Pages 23-27

  Sheppard, John D ^a   Stephen V Scoper, ^a   Sandeep Samudre, ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; LOTEPREDNOL ETABONATE;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONJUNCTIVA DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; EMULSION; FEMALE; HUMAN; INJECTION SITE STINGING; LACRIMAL FLUID; MALE; PREMEDICATION; STAINING;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANDROSTADIENES; CHRONIC DISEASE; COHORT STUDIES; CYCLOSPORINE; DRY EYE SYNDROMES; EYE PAIN; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 79951981791     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2010.0085     Document Type: Article

References (22)

1. Sheppard, J.D., ed. Dry eye syndrome. Pharm. Ther. Dig. 28(Suppl):1-45, 2003.
2. Stern, M.E., Beuerman, R.W., Fox, R.I., Gao, J., Mircheff, A.K., and Pflugfelder, S.C. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea 17:584-589, 1998. (Pubitemid 28511901)
3. Pflugfelder, S.C. Integrating Restasis into the management of dry eye. Int. Ophthalmol. Clin. 46:101-103, 2006.
4. Holland, E.J., Karpecki, P.M., Lindstrom, R.L., et al. Dry eye management in the postoperative patient. Cataract Refract. Surg. Today 3(Suppl):1-12, 2003.
5. Lemp, M.A. Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. CLAOJ. 21:221-232, 1995.
6. International Dry Eye Workshop. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop. Ocul. Surf. 5:75-92, 2007.
7. Sullivan, D.A., Sullivan, B.D., Evans, J.E., et al. Androgen deficiency, meibomian gland dysfunction, and evaporative dry eye. Ann. N. Y. Acad. Sci. 966:211-222, 2002.
8. Pflugfelder, S.C., Solomon, A., and Stern, M.E. The diagnosis and management of dry eye: a twenty-five-year review. Cornea 19:644-649, 2000.
9. Samudre, S.S., Lattnazio, F.A., Williams, P.B., and Sheppard, J.D. Comparison of topical steroids for acute anterior uveitis. J. Ocul. Pharmacol. Ther. 20:533-547, 2004.
10. Bron, A.J., Evans, V.E., and Smith, J.A. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 22:640-650, 2003. (Pubitemid 37175145)
11. Berntsen, D.A., Mitchell, G.L., and Nichols, J.J. Reliability of grading lissamine green conjunctival staining. Cornea 25:695-700, 2006. (Pubitemid 44671859)
12. Bartlett, J.D., Horwitz, B., Laibovits, R., et al. Intraocular pressure response to loteprednol etabonate in known steroid responders. J. Ocul. Pharmacol. 9:157-165, 1993.
13. Ilyas, H., Slonim, C.B., Braswell, G.R., Favetta, J.R., and Schulman, M. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis. Eye Contact Lens 30:10-13, 2004. (Pubitemid 43196972)
14. Holland, E.J., Djalilian, A.R., and Sanderson, J.P. Attenuation of ocular hypertension with the use of loteprednol etabonate 0.5% in steroid responders after corneal transplantation. Cornea 28:1139-1143, 2009.
15. Druzgala, P., Hochhaus, G., and Bodor, N. Soft drugs-10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate. J. Steroid Biochem. Mol. Biol. 38:149-154, 1991.
16. Behrens, A., Doyle, J.J., Stern, L., et al. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea 25:900-907, 2006. (Pubitemid 44763848)
17. Sall, K., Stevenson, O.D., Mundorf, T.K., and Reis, B.L. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 107:631-639, 2000. (Pubitemid 30191329)
18. Slonim, C.B. The ocular allergic response. Rev. Ophthalmol. 8:101-112, 2000.
19. Lotemax (loteprednol etabonate ophthalmic suspension) prescribing information package insert, May 2005, Bausch & Lomb, Inc., Rochester, NY.
20. Pavesio, C.E., and Decory, H.H. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br. J. Ophthalmol. 92:455-459, 2008.
21. Restasis™ (cyclosporine 0.05% emulsion) prescribing information package insert, January 2002, Allergan, Inc., Irvine,CA.
22. Sheppard, J.D. Topical loteprednol pre-treatment reduces cyclosporine stinging. Presented at the ASCRS Symposium on Cataract, IOL, and Refractive Surgery, Washington, DC, 2005.